From the limited number of patients with plasma collected at the time of PD during EGFR-TKI treatment, we found that irrespective of the response of the tumor (CR, PR, SD, or PD), miR-107 and miR-195 expression levels at the time of PD exhibited a tendency to return to pre-treatment levels in the majority of patients. The gene discussed is EGFR; the disease is neoplasm.